| Sunday, March 22 |
|
3:00 - 7:30 PM
|
Registration
|
Longs Peak Foyer
|
|
6:30 - 7:30 PM
|
Refreshments
|
Longs Peak Foyer
|
|
7:30 - 9:30 PM
|
Keynote Address (Joint)
|
Longs Peak / Grays Peak
|
|
*
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC
|
|
|
*
Didier Trono,
Ecole Polytechnique Fédérale de Lausanne
|
|
|
|
|
|
Francoise Barré-Sinoussi,
Institut Pasteur
HIV Diversity and Pathogenesis
|
|
|
Rafi Ahmed,
Emory University School of Medicine
Vaccination and Immune Memory
|
|
| Monday, March 23 |
|
7:00 - 8:00 AM
|
Breakfast
|
Red Cloud / Shavano / Torreys
|
|
8:00 - 11:00 AM
|
Host Genomics and HIV Disease (Joint)
|
Columbine Ballroom
|
|
*
Didier Trono,
Ecole Polytechnique Fédérale de Lausanne
|
|
|
Amalio Telenti,
Centre Hospitalier Universitaire Vaudois
Evolutionary and Integrative Genomics of Susceptibility to HIV
|
|
|
Mary Carrington,
NCI, National Institutes of Health
Immunogenetic Variation Characterizing Exceptional Control of HIV
|
|
|
|
|
|
Bruce D. Walker,
Ragon Institute of MGH, MIT and Harvard
HIV Controllers: A Model for T Cell Vaccination?
|
|
|
Ioannis Theodorou,
INSERM U543
Short Talk: Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study
|
|
|
David I. Watkins,
University of Wisconsin-Madison
Vaccine-Induced Cellular Responses Control Acute SIV Replication after Heterologous Challenge
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Longs Peak Foyer
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Red Cloud / Shavano / Torreys
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Red Cloud / Shavano / Torreys
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Longs Peak Foyer
|
|
5:00 - 7:15 PM
|
The Bigger Picture: Microbicides, Circumcision and Drugs for Prevention
|
Quandary
|
|
|
|
|
*
Glenda Gray,
University of the Witwatersrand
|
|
|
Bertran Auvert,
CHU Ambroise Paré
Circumcision: Uptake and Impact
|
|
|
Minh H. Dinh,
Northwestern University Feinberg School of Medicine
Short Talk: HIV-1 Interactions with Adult Human Penile Epithelium
|
|
|
Barbara L. Shacklett,
University of California, Davis
Short Talk: Do Mucosal T Cell Responses to HIV-1 Matter?
|
|
|
Carolina Herrera,
St. George's University of London
Short Talk: Early Colorectal Responses to HIV-1 and Modulation by Microbicides
|
|
|
Gilda Tachedjian,
Burnet Institute
Short Talk: Enhancement of HIV-1 Infection is Not Intrinsic to Polyanion-Based Microbicides
|
|
|
Myron S. Cohen,
University of North Carolina Chapel Hill
Antiretroviral Therapy to Prevent Sexual Transmission of HIV-1
|
|
|
7:15 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Red Cloud / Shavano / Torreys
|
|
7:30 - 10:00 PM
|
Poster Session 1
|
Red Cloud / Shavano / Torreys
|
| Tuesday, March 24 |
|
7:00 - 8:00 AM
|
Breakfast
|
Red Cloud / Shavano / Torreys
|
|
8:00 - 11:00 AM
|
Immune Control of HIV and Virus Escape (Joint)
|
Columbine Ballroom
|
|
|
|
|
|
|
|
*
Bruce D. Walker,
Ragon Institute of MGH, MIT and Harvard
|
|
|
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois
Immune Correlates of Protection to HIV
|
|
|
Joseph M. McCune,
University of California, San Francisco
Short Talk: Immune Control in Pathogenic and Nonpathogenic SIV Infection
|
|
|
Mark Connors,
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Short Talk: Effective Control of HIV by CD8+ T-Cells is Associated with Infected CD4+ T Cell Elimination: Ramifications for T Cell Based Vaccines
|
|
|
Carl W. Dieffenbach,
NIAID, National Institutes of Health
Short Talk: Stimulus Package: NIH and the ARRA
|
|
|
Philip J. Goulder,
University of Oxford
HIV Escape and T-Cell Control of HIV
|
|
|
George M. Shaw,
University of Alabama at Birmingham
HIV-1 Sequences in Acute and Early Infection Reveal the Genetic Identity, Biological Phenotype, and Precise Evolutionary Pathways of Transmitted/Founder Viruses and their Progeny
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Longs Peak Foyer
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Red Cloud / Shavano / Torreys
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Red Cloud / Shavano / Torreys
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Longs Peak Foyer
|
|
5:00 - 7:15 PM
|
How to Improve Vaccine Efficacy? Adjuvants, Route of Administration...
|
Quandary
|
|
*
David I. Watkins,
University of Wisconsin-Madison
|
|
|
Bali Pulendran,
Emory University
Modulating Vaccine Responses with Innate Immunity
|
|
|
Susan W. Barnett,
Novartis Vaccines and Diagnostics, Inc.
HIV Antigen Discovery and Novel Vaccine Deliveries Using Recombinant Alphavirus Replicon Particles and Adjuvanted Proteins
|
|
|
Christopher J. Miller,
University of California, Davis
A T Cell Vaccine that Elicits Mucosal CD8+ Effector Cells in a Setting of Minimal Immune Activation Can Protect Rhesus Monkeys from Vaginal SIV Challenge
|
|
|
Barbara K. Felber,
National Cancer Institute, National Institutes of Health
Short Talk: Electroporation of Optimized DNA Vaccines Leads to Greatly Enhanced Systemic and Mucosal Immune Responses and Control of Pathogenic SIVmac251 Challenge: Antibodies Contribute to Virus Containment
|
|
|
Johannes Fabian Scheid,
Rockefeller University
Short Talk: Search for Broadly Neutralizing Antibodies against HIV using a Single Cell Approach
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Red Cloud / Shavano / Torreys
|
|
7:30 - 10:00 PM
|
Poster Session 2
|
Red Cloud / Shavano / Torreys
|
| Wednesday, March 25 |
|
7:00 - 8:00 AM
|
Breakfast
|
Red Cloud / Shavano / Torreys
|
|
8:00 - 11:00 AM
|
How to Generate Vaccine Efficacy against HIV? T Cell-Based and B-Cell Based Vaccines
|
Quandary
|
|
*
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois
|
|
|
Barton F. Haynes,
Duke University Medical Center
What Does a Successful HIV-1 Vaccine Need To Do? Clues From Acute HIV-1 Infection
|
|
|
Dan H. Barouch,
Beth Israel Deaconess Medical Center
Novel Adenovirus Vector-Based Vaccines for HIV-1
|
|
|
Dennis R. Burton,
The Scripps Research Institute
Mechanisms of Antibody Protection Against HIV
|
|
|
Peter D. Kwong,
Vaccine Research Center, National Institutes of Health
Structure-Based Envelope Immunogens
|
|
|
Amitinder Kaur,
New England Regional Primate Research Center
Short Talk: Protective Efficacy of a Replication-Defective Herpes Simplex Virus-based AIDS Vaccine Against High Dose Intra-Rectal SIVmac239 Challenge
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Longs Peak Foyer
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Red Cloud / Shavano / Torreys
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Red Cloud / Shavano / Torreys
|
|
2:30 - 4:30 PM
|
Workshop 1: Which Immune Correlates of Protection against HIV? How to Measure T Cell and B Cell Correlates? Supported in part by the French Agency for AIDS Research (ANRS)
|
Quandary
|
|
*
Richard A. Koup,
National Institutes of Health
|
|
|
Asier Sáez-Cirión,
Institut Pasteur
The Strong HIV Suppressive Capacity of CD8+ T Cells from HIV Controllers is Associated with Gag-Specific CD8+ T Cell Responses
|
|
|
Adam R. Hersperger,
University of Pennsylvania
HIV-Specific CD8 T Cells from Elite Controllers Rapidly Upregulate Perforin
|
|
|
Meritxell Genescà,
University of California, Davis
For the CD8+ T Cells to be Effective in the Context of a Live-Attenuated Vaccine Differential Immune Activation is Critical
|
|
|
Jorge Almeida,
INSERM U543
Antigen Sensitivity is a Major Determinant of CD8+ T Cell Efficacy in HIV-1 Infection
|
|
|
Leonidas Stamatatos,
Seattle Biomedical Research Institute
Broad Neutralizing Antibody Responses during HIV-1 Infection: Prevalence and Epitope Specificities
|
|
|
Nicole A. Doria-Rose,
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Breadth of Neutralizing Antibodies in HIV+ Serum: Clustering Analysis and Association with Clinical Variables
|
|
|
Ann J. Hessell,
The Scripps Research Institute
Complete Protection Provided by Antibodies 2F5 and 4E10 Against Mucosal SHIV BaL Challenge
|
|
|
Vincent Holl,
Institute of Virology
Identification of HIV-Specific IgG that Inhibit Infection of Mucosal HIV Target Cells
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Longs Peak Foyer
|
|
5:00 - 7:00 PM
|
HIV at the Mucosa: Portal of Entry and Front-Line Defense (Joint)
|
Columbine Ballroom
|
|
*
Daniel C. Douek,
NIAID, National Institutes of Health
|
|
|
†,
|
|
|
Ashley T. Haase,
University of Minnesota
Keynote Address: Quest for Design Principles for an Effective HIV Vaccine/Microbicide in Studies of SIV Pathogenesis
|
|
|
Alison Simmons,
Weatherall Institute of Molecular Medicine
Dendritic Cell Factors Required for HIV-1 Infection
|
|
|
Ronald S. Veazey,
Tulane National Primate Research Center
_7 Integrin Expression on CD4+ T Cells as a Surrogate Marker for Tracking Intestinal CD4+ T Cell Loss in SIV Infection
|
|
|
Satya Dandekar,
University of California, Davis
Short Talk: Mechanisms of Impaired Gut Mucosal Defenses during HIV and SIV Infections
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Red Cloud / Shavano / Torreys
|
|
7:30 - 10:00 PM
|
Poster Session 3
|
Red Cloud / Shavano / Torreys
|
| Thursday, March 26 |
|
7:00 - 8:00 AM
|
Breakfast
|
Red Cloud / Shavano / Torreys
|
|
7:00 - 8:00 AM
|
Poster Setup
|
Red Cloud / Shavano / Torreys
|
|
8:00 - 11:15 AM
|
HIV-HSV-2 Interactions and Lessons from Clinical Trials of Preventative Vaccines
|
Quandary
|
|
|
|
|
Lawrence Corey,
Fred Hutchinson Cancer Research Center
Mechanism behind the HSV-2-HIV Interaction: Subclinical Persistence of HIV Receptor Positive Cells
|
|
|
*
Scott M. Hammer,
Columbia University
Challenges in Preventative Vaccine Development
|
|
|
Susan P. Buchbinder,
San Francisco Department of Public Health
Clinical Endpoints in the Step Study
|
|
|
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center
Lessons from the HIV-Ad5 Vaccine Phase II Clinical Trial
|
|
|
Merlin L. Robb,
Walter Reed Army Institute of Research
Lessons from the Thai ALVAC-gp120 HIV Vaccine Efficacy Trial: A Community Based Study
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Longs Peak Foyer
|
|
11:00 AM - 12:00 PM
|
Lunch
|
Red Cloud / Shavano / Torreys
|
|
12:00 - 2:30 PM
|
Poster Session 4
|
Red Cloud / Shavano / Torreys
|
|
2:30 - 4:30 PM
|
Workshop 2: Clinical Trials Design. Supported in part by the French Agency for AIDS Research (ANRS)
|
Quandary
|
|
*
Scott M. Hammer,
Columbia University
|
|
|
Dean Follmann,
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Crossover Designs for HIV Prevention Trials
|
|
|
Peter Gilbert,
Fred Hutchinson Cancer Research Center
Leveraging Baseline Characteristics to Improve Prevention Trials
|
|
|
Frances Priddy,
International AIDS Vaccine Initiative
HIV Vaccines and PrEP
|
|
|
|
|
|
Heather B. Jaspan,
University of Cape Town
HIV Vaccine Trials in Adolescents
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Longs Peak Foyer
|
|
5:00 - 7:00 PM
|
Prevention of AIDS: What can we Learn from Therapeutic Vaccines
|
Quandary
|
|
|
|
|
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC
Lessons for Therapeutic Vaccines against HIV for Immune Correlates of Protection against HIV
|
|
|
*
Rafick-Pierre Sekaly,
University of Montreal
Improving and Modeling of Therapeutic Autologous Dendritic Cell Vaccine for HIV-1 Infection
|
|
|
|
|
|
Stephen J. Kent,
University of Melbourne
Short Talk: Reduced Viremia and Delayed Disease Progression Following Immunotherapy of SIV with Antigen Pulsed Blood
|
|
|
Glenda Gray,
University of the Witwatersrand
HIV Vaccine Trials in South Africa: Looking Forward from Phambili
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Red Cloud / Shavano / Torreys
|
|
8:00 - 11:00 PM
|
Entertainment
|
Red Cloud / Shavano / Torreys
|
| Friday, March 27 |
|
|
Departure
|
|
